Please assess the completion status of the following clinical trial:

Trial Title: To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Female patient with histologically or cytologically documented breast adenocarcinoma~2. First local or metastatic relapse~3. Patients must have received a prior neoadjuvant or adjuvant Taxotere®-based chemotherapy regimen, provided this chemotherapy was completed \> than or = to 12 months prior to enrollment date~4. Prior hormone or immune therapy is allowed. Antitumoral adjuvant hormone therapy may be continued during the study period, provided it was started \> 12 months prior to study enrollment~5. Her2/neu negative tumor demonstrated by immunohistochemistry (IHC 0 or 1+) or by fluorescence in situ hybridation (FISH -). A patient with tumor assessed as 2+ by IHC can be enrolled if the tumor is negative by FISH.~6. ECOG performance status of 0 to 2~7. Normal cardiac function confirmed by LVEF or shortening fraction (MUGA scan or echocardiography, respectively, within normal limits for the institution) assessed within 3 months prior to study entry. An ECG must be obtained within 4 weeks prior study entry and must demonstrate no clinically significant abnormality.~8. Patients are required to have at least one measurable lesion according to RECIST guidelines~9. Adequate organ function defined by:~   1. Hematology: Neutrophils \> than or = to 2.0 109/L, Platelets \> than or = to 100 109/L, Hemoglobin \> than or = to 10 g/dL~  2. Hepatic function: Total bilirubin within normal limits, AST (SGOT) and ALT (SGPT) \< than or = to 1.5 UNL, alkaline phosphatase \< than or = to 2.5 UNL (unless accompanied by extensive bone metastases)~10. Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of childbearing potential~11. Written informed consent prior to beginning specific protocol procedures must be obtained and documented according to the local regulatory requirements~Exclusion Criteria~1. Prior therapy for advanced or recurrent disease~2. Previous cumulative exposure to epirubicin \> 600 mg/m² or to doxorubicin \> 300 mg/m²~3. Previous radiation therapy having involved more than 25% of bone marrow; incomplete recovery from toxicity of radiation therapy~4. Symptomatic brain metastases and clinically diagnosed leptomeningeal metastases~5. Isolated unmeasurable bone lesions, serous pleural effusion or pulmonary lymphangiitis (i.e., unmeasurable disease according to the RECIST guidelines)~6. Pre-existing motor or sensory neurologic toxicity of a severity \> than or = to grade 2 according to NCI-CTC AE criteria version 3.0~7. Pregnant or lactating women or women of childbearing potential not using adequate contraception~8. Other serious illness or medical conditions, including:~   1. Congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias~  2. History of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would hamper understanding and giving informed consent.~  3. Active uncontrolled infection~  4. Active peptic ulcer, uncontrolled diabetes mellitus~9. Past or current history of neoplasm other than breast carcinoma, except:~   1. Curatively treated non-melanoma skin cancer.~  2. in situ carcinoma of the cervix.~  3. Other cancer curatively treated and with no evidence of disease for at least 10 years~10. Chronic treatment with corticosteroids unless initiated \> 6 months prior to study entry and at low dose (\< than or = to 20 mg methylprednisolone per day or equivalent)~11. Definite contraindications for the use of corticosteroids~12. Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol (see Section 6.2)~13. Concurrent treatment with other investigational drugs. Active treatment as part of another clinical therapeutic trial within 30 days prior to study entry~14. Concurrent treatment with any other anti-cancer therapy, except adjuvant hormone therapy started \> than or = to 12 months prior to study enrollment. Bisphosphonates for management of bone metastases or osteoporosis/osteopenia are allowed~15. History of hypersensitivity to docetaxel (or drugs formulated in polysorbate 80), epirubicin or doxorubicin~16. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study~17. Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues